These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30231203)

  • 1. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
    Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
    ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy.
    Zhao J; Wang H; Hsiao CH; Chow DS; Koay EJ; Kang Y; Wen X; Huang Q; Ma Y; Bankson JA; Ullrich SE; Overwijk W; Maitra A; Piwnica-Worms D; Fleming JB; Li C
    Biomaterials; 2018 Mar; 159():215-228. PubMed ID: 29331808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.
    Blair AB; Kim VM; Muth ST; Saung MT; Lokker N; Blouw B; Armstrong TD; Jaffee EM; Tsujikawa T; Coussens LM; He J; Burkhart RA; Wolfgang CL; Zheng L
    Clin Cancer Res; 2019 Sep; 25(17):5351-5363. PubMed ID: 31186314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
    Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U
    Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.
    Elahi-Gedwillo KY; Carlson M; Zettervall J; Provenzano PP
    Cancer Res; 2019 Jan; 79(2):372-386. PubMed ID: 30401713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer.
    Chen Y; Wang L; Luo S; Hu J; Huang X; Li PW; Zhang Y; Wu C; Tian BL
    Drug Des Devel Ther; 2020; 14():2945-2957. PubMed ID: 32801636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
    Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
    Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
    [No Abstract]   [Full Text] [Related]  

  • 11. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
    Ahmad G; Mackenzie GG; Egan J; Amiji MM
    Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.
    Zhao J; Wen X; Tian L; Li T; Xu C; Wen X; Melancon MP; Gupta S; Shen B; Peng W; Li C
    Nat Commun; 2019 Feb; 10(1):899. PubMed ID: 30796212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
    Li J; Yuan S; Norgard RJ; Yan F; Yamazoe T; Blanco A; Stanger BZ
    Cancer Immunol Res; 2020 Mar; 8(3):282-291. PubMed ID: 31871120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.
    Mehra S; Garrido VT; Dosch AR; Lamichhane P; Srinivasan S; Singh SP; Zhou Z; De Castro Silva I; Joshi C; Ban Y; Datta J; Gilboa E; Merchant NB; Nagathihalli NS
    Cancer Res Commun; 2023 Jul; 3(7):1224-1236. PubMed ID: 37448553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy.
    Gaikwad S; Srivastava SK
    Mol Ther; 2024 Sep; 32(9):3145-3162. PubMed ID: 39097773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
    Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Rückert F; Grützmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA
    Science; 2009 Jun; 324(5933):1457-61. PubMed ID: 19460966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal Homeostasis-Restoring Nanomedicine Enhances Pancreatic Cancer Chemotherapy.
    Yu N; Zhang X; Zhong H; Mu J; Li X; Liu T; Shi X; Liang XJ; Guo S
    Nano Lett; 2022 Nov; 22(21):8744-8754. PubMed ID: 36279310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
    Ernsting MJ; Hoang B; Lohse I; Undzys E; Cao P; Do T; Gill B; Pintilie M; Hedley D; Li SD
    J Control Release; 2015 May; 206():122-30. PubMed ID: 25804872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.